11 Results Found
Our commitment to HIV treatments and prevention through the years
HIV (human immunodeficiency virus) continues to be a major public health threat. The virus can lead to AIDS. Since 1985, our company has been engaged in research and development (R&D) efforts in the prevention and treatment of HIV. Over the years, our scientists have made significant discoveries that changed the way HIV is treated. Here […]
At MSD Switzerland, diversity and inclusion are central to our company culture.
MSD tradition of Diversity Diversity and Inclusion are not mere words for us – they embody the reason we are able to realize our corporate purpose: We harness the power of cutting-edge research to save and improve lives around the world. MSD as an employer Would you like to work with us to further develop […]
Our purpose: We use the power of leading-edge science to save and improve lives around the world We focus on disease areas with unmet medical need Find out more about our main areas of focus. CH-NON-00617, 02/2026
Clinical trials in Switzerland
MSD’s clinical study program in Switzerland (as of 01/2026) (published on www.clinicaltrials.gov) For an overview of studies throughout Switzerland that are looking for participants, visit www.humanforschung-schweiz.ch CH-NON-00136, 01/2026
https://www.msd.ch/en/home/research/clinical-trials/clinical-trials-in-switzerland/
World AIDS Day 2025: Research remains key
>> Go to all press releases World AIDS Day 2025: Research remains key Lucerne, December 1, 2025 – World AIDS Day was launched in 1988.1 Held every year on December 1 since then, it serves as a reminder that the human immunodeficiency virus, or HIV for short, continues to pose a challenge to public health.4 At […]
CAPVAXIVE – Publication of clinical trial results
Publication of clinical trial results The information given below and the relevant links to the clinical data fulfil the requirements of Articles 71-73 of the Ordinance on Therapeutic Products (Therapeutic Products Ordinance, TPO). They supplement the information published in association with the Swiss marketing authorisation for the medicinal product.. CAPVAXIVE® CAPVAXIVE® (Pneumococcal 21-valent conjugate vaccine), […]
https://www.msd.ch/en/capvaxive-veroffentlichung-der-ergebnisse-klinischer-studien/
HIV Our legacy in innovative HIV science continues We remember when HIV was one of society’s most daunting challenges, when millions of people lost their lives to the devastating AIDS epidemic. Our scientists embarked on an urgent mission to unravel and understand the virus, which led to groundbreaking research in HIV. We are still driven […]
https://www.msd.ch/en/home/about-us/areas-of-focus/infectious-diseases/
Our Milestones in Switzerland MSD Switzerland – Who We Are Today As of 2025 we will be operating in the Rösslimatt area of Lucerne We are pleased to be bringing together three of MSD’s five branches in the Rösslimatt area. More information CH-NON-02244, 05/2025
